Clinical trials: Anti-Glaucoma Medications
Open Angle Glaucoma, Ocular Hypertension
A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Slow release formulation of latanoprost is compared for safety and pressure-lowering efficacy with topically administration of commercially available latanoprost in patient with glaucoma and ocular hypertension
- Trial name
- NCT02129673
- Testing
- VS101 Insert Dose A, VS101 Insert Dose B, VS101 Insert Dose C
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- ViSci Ltd.
Glaucoma
VividWhite Glaucoma Implant (VW-51) Pivotal Study
The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51…
- Trial name
- NCT06176170
- Testing
- VividWhite Glaucoma Implant (VW-51)
- Where
- 6 sites in Australia
- Volunteers
- 65 people
- Sponsor
- VividWhite Pty Ltd
Open Angle Glaucoma
A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction
The purpose of this study is to compare the safety and efficacy of goniotomy performed with a novel ophthalmic knife compared to trabecular bypass stent implantation in mild to moderate glaucoma subjects who are also undergoing…
- Trial name
- NCT02784249
- Testing
- Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
- Where
- United States
- Volunteers
- 166 people
- Sponsor
- New World Medical, Inc.
Elevated Intraocular Pressure
A Study of AR-12286 in Patient With Elevated Intraocular Pressure (IOP)
Double-masked, randomized, multi-center, placebo-controlled parallel-comparison of AR-12286.
- Trial name
- NCT00902200
- Testing
- AR-12286, AR-12286 vehicle
- Where
- 8 sites in United States
- Volunteers
- 89 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Glaucoma Treatment by Cyclo-coagulation Using High Intensity Focused Ultrasound (HIFU)
The purpose of this study is to evaluate the effectiveness and the safety of the cyclocoagulation using High Intensity Focused Ulatrsound with the EYEOP1 device in glaucoma patients
- Trial name
- NCT01592955
- Testing
- EYEOP1
- Where
- 7 sites in Israel, Italy and 2 more
- Volunteers
- 84 people
- Sponsor
- EyeTechCare
Open Angle Glaucoma, Ocular Hypertension
24-hour Efficacy of AR-12286
An open-label, non-comparative, pilot evaluation of the 24-hour ocular hypotensive efficacy of AR-12286 in patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT01330979
- Testing
- AR-12286 0.5% Ophthalmic Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
A Study Assessing PG286 Ophthalmic Solution, 0.5% Compared to Its Individual Components for 28 Days
In the double-masked, randomized, multi-center, active-controlled parallel study, patients will be randomized to receive either a fixed dose combination of AR-12286 and travoprost, AR-12286, or travoprost.
- Trial name
- NCT01789736
- Testing
- PG286 Ophthalmic Solution 0.5%, AR-12286 Ophthalmic Solution 0.5%, Travoprost Ophthalmic Solution 0.004%
- Where
- 21 sites in United States
- Volunteers
- 234 people
- Sponsor
- Aerie Pharmaceuticals
Refractory Glaucoma
Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma.
- Trial name
- NCT04303897
- Testing
- XEN Glaucoma Stent
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Next Generation Rocklatan
The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).
- Trial name
- NCT06441643
- Testing
- AR-17043 Ophthalmic Solution, PG043 Ophthalmic Solution, Latanoprost 0.005% Ophthalmic Solution
- Where
- 12 sites in United States
- Volunteers
- 426 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
AR-12286 in Combination With Latanoprost
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
- Trial name
- NCT01302249
- Testing
- Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma, Ocular Hypertension
AR-12286 Fixed Dose Combination to Lower Elevated Intraocular Pressure
This is a double-masked, randomized, controlled study assessing the safety and ocular hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to Travatan® Z in patients with elevated intraocular…
- Trial name
- NCT01474135
- Testing
- 0.25% AR-12286 / 0.004% travoprost, 0.5% AR-12286, 0.004% travoprost, 0.004% Travoprost
- Where
- 9 sites in United States
- Volunteers
- 93 people
- Sponsor
- Aerie Pharmaceuticals
Glaucoma
Ocular Hypotensive Efficacy of AR-102
A double-masked, randomized, vehicle-controlled, dose-response study assessing the safety and ocular hypotensive efficacy of AR-102 in subjects with elevated intraocular pressure.
- Trial name
- NCT00523250
- Testing
- AR-102 0.003% Ophthalmic Solution, AR-102 0.005% Ophthalmic Solution, AR-102 0.01% Ophthalmic Solution
- Where
- 8 sites in United States
- Volunteers
- 82 people
- Sponsor
- Aerie Pharmaceuticals
Elevated Intraocular Pressure
Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure
Prospective, double-masked, randomized, multi-center, active-controlled, parallel-group, 3-month study assessing the safety and ocular hypotensive efficacy of TearClear latanoprost Ophthalmic Solution, 0.005% (TC-002) compared to…
- Trial name
- TC-002-301 (NCT05165290)
- Testing
- Latanoprost ophthalmic solution, 0.005%, TC-002 latanoprost ophthalmic solution, 0.005%
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- TearClear Corp
Open-angle Glaucoma, OAG
A Study to Evaluate Adverse Events and Change in Disease Activity With the XEN45 Glaucoma Treatment System Implantation In Adult Participants With Open-Angle Glaucoma in China
Glaucoma is the second most common cause of blindness in the world, second only to cataracts. The purpose of this study is to assess adverse events (AEs) and changes in disease activity in participants with open-angle glaucoma…
- Trial name
- NCT05821855
- Testing
- XEN45 Glaucoma Treatment System, Trabeculectomy
- Where
- 13 sites in China
- Volunteers
- 120 people
- Sponsor
- AbbVie
Glaucoma
Clinical Study of the Safety and Performance of the Miami InnFocus Drainage Implant to Relieve Glaucoma Symptoms
Assess the safety and performance of the Miami InnFocus Drainage Implant in patients suffering from glaucoma that is inadequately controlled on tolerated medical therapy with intraocular pressure greater than or equal to 18 mm Hg…
- Trial name
- NCT00772330
- Testing
- Glaucoma Drainage Device
- Where
- Dominican Republic
- Volunteers
- 23 people
- Sponsor
- InnFocus Inc.
Glaucoma, Open-Angle
A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure
This is a prospective, parallel-comparison, multi-center, double-masked, randomized, vehicle-controlled dose-response study assessing the safety and ocular hypotensive efficacy of VVN539 in subjects with POAG or OHT.
- Trial name
- NCT05451329
- Testing
- VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- VivaVision Biotech, Inc
Glaucoma
Satisfaction With XEN Gel Stent Versus Trabeculectomy for the Treatment of Glaucoma
This is a prospective, observational, non-interventional study of patients scheduled to receive surgical intervention either via XEN or trabeculectomy for open-angle glaucoma.
- Trial name
- XENPRO (NCT03852810)
- Where
- 10 sites in Canada, Germany and 1 more
- Volunteers
- 28 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT02057575
- Testing
- PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Where
- 23 sites in United States
- Volunteers
- 298 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Ocular Hypertension, Open Angle Glaucoma
Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
- Trial name
- NCT01731002
- Testing
- AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, Latanoprost ophthalmic solution 0.005%
- Where
- 22 sites in United States
- Volunteers
- 224 people
- Sponsor
- Aerie Pharmaceuticals